A report released this week by some of the nation’s leading biopharmaceutical research companies says 537 medicines are currently being developed for the nearly 100 million Americans who are affected by neurological disorders. We have seen a string of failures in Alzheimer’s research, and yet this report shows that there are still many companies that are still committed to finding a successful molecule. The failures have just taught us where else to look.”But the research and thus potential for treatment goes far beyond even Alzheimer’s disease. According to PhRMA, because neurological disorders are more prevalent in older adults and people are living longer as a result of decreases in the number of deaths from cardiovascular disease and cancer, there is an unprecedented increase in the number of people affected by neurological disorders. Scientists in the biopharmaceutical arena are uncovering more about how the nervous system works at the molecular and genetic levels, and thus driving the development of innovative treatments for several neurological disorders.

Source: Forbes April 27, 2018 20:37 UTC